by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C

Slides:



Advertisements
Similar presentations
Treosulfan-based conditioning regimens for hematopoietic stem cell transplantation in children with primary immunodeficiency: United Kingdom experience.
Advertisements

A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,
Stem cell concepts renew cancer research by John E. Dick Blood Volume 112(13): December 15, 2008 ©2008 by American Society of Hematology.
Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.
A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.
Interim Results from a Phase 2, Multicenter, Single-Arm Study to Evaluate the Safety and Efficacy of Deferasirox after Hematopoietic Stem Cell Transplantation.
A Randomized Phase 3 Study of Peripheral Blood Progenitor Cell Mobilization With Stem Cell Factor and Filgrastim in High-Risk Breast Cancer Patients by.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee 
Comparable results of umbilical cord blood and HLA-matched sibling donor hematopoietic stem cell transplantation after reduced-intensity preparative regimen.
by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E
Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,
Successful Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant in an Acute Leukemia Patient With Chemotherapy-Induced Marrow Aplasia and Progressive.
Female donors contribute to a selective graft-versus-leukemia effect in male recipients of HLA-matched, related hematopoietic stem cell transplants by.
The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and.
Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning by Navneet S. Majhail, Ruta Brazauskas,
Solid cancers after allogeneic hematopoietic cell transplantation
by Thomas Rasmussen, Linda Jensen, Lone Honoré, and Hans Erik Johnsen
Nonmyeloablative conditioning for relapsed follicular lymphoma
Superior Survival after Autologous vs
The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma  Mehdi Hamadani, Erinn Hade, Don M. Benson,
Autologous Transplantation Therapy for Chronic Myelogenous Leukemia
Functional neutrophils from human ES cells
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients by William J. Hogan,
What is a true ALCL? by Wolfram Klapper Blood Volume 124(9):
166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials by.
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase by Jiří Pavlů,
Blood Volume 92(10): November 15, 1998
High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.
by Jayesh Mehta Blood Volume 112(2): July 15, 2008
by Douglas D. Ross, Judith E. Karp, Tar T. Chen, and L. Austin Doyle
Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes 
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors  Kenneth.
A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is.
Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma:
by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T
Impact of Donor Characteristics and HLA Matching on Survival of Chinese Patients with Hematologic Malignancies Undergoing Unrelated Hematopoietic Stem.
Low Dose Thymoglobulin Results In Improved Outcomes After Allogeneic Unrelated Hematopoietic Stem Cell Transplantation (HCT) For Patients With Acute Myeloid.
Sabina Kersting, Leo F. Verdonck 
Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation  Gita Thanarajasingam, Haesook T. Kim,
Chronic graft-versus-host disease
Pretransplantation Supportive and Palliative Care Consultation for High-Risk Hematopoietic Cell Transplantation Patients  Elizabeth T. Loggers, Thomas.
New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation  Anita D'Souza,
Phase I Study of Clofarabine and 2-Gy Total Body Irradiation as a Nonmyeloablative Preparative Regimen for Hematopoietic Stem Cell Transplantation in.
Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation  Vijaya.
Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck 
Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence  Keshav.
by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc
Trajectories of Quality of Life after Hematopoietic Cell Transplantation: Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network 0902.
Volume 2(Supplement 1):1-3
What is quality in a transplant program?
Non-CD34+ Cells, Especially CD8+ Cytotoxic T Cells and CD56+ Natural Killer Cells, Rather Than CD34 Cells, Predict Early Engraftment and Better Transplantation.
The Outcomes of Family Haploidentical Hematopoietic Stem Cell Transplantation in Hematologic Malignancies Are Not Associated with Patient Age  Lujia Dong,
by Mieke Aldenhoven, Brigitte T. A. van den Broek, Robert F
Volume 2(Supplement 1):46-49
Treatment of Autoimmune Disease by Intense Immunosuppressive Conditioning and Autologous Hematopoietic Stem Cell Transplantation by Richard K. Burt, Ann.
Bridge to transplant following Bv+Bs regimen.
Mammen Chandy  Biology of Blood and Marrow Transplantation 
Treatment versus Transplant for Challenging Hematologic Disorders
Survival based on V gene mutation status and CD38 expression among B-CLL patients who stratify to the Rai intermediate risk category. Survival based on.
William Berquist, MD  Gastrointestinal Endoscopy 
Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation  Marco Mielcarek, Barry.
TP53 Mutations in AML Predict Adverse Outcome in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant by Bartlomiej M Getta, Arnab Ghosh,
Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.
by Lucy A. Godley, and Akiko Shimamura
by Jan J. Cornelissen, and Didier Blaise
by Victor A. Chow, Mazyar Shadman, and Ajay K. Gopal
Cold agglutinin disease
Presentation transcript:

Meeting the challenge of hematologic malignancies in sub-Saharan Africa by Satish Gopal, William A. Wood, Stephanie J. Lee, Thomas C. Shea, Kikkeri N. Naresh, Peter N. Kazembe, Corey Casper, Peter B. Hesseling, and Ronald T. Mitsuyasu Blood Volume 119(22):5078-5087 May 31, 2012 ©2012 by American Society of Hematology

Distribution of radiotherapy and hematopoietic stem cell transplant services in sub-Saharan Africa. Satish Gopal et al. Blood 2012;119:5078-5087 ©2012 by American Society of Hematology

A conceptual framework to improve survival among patients with hematologic malignancies in sub-Saharan Africa. A conceptual framework to improve survival among patients with hematologic malignancies in sub-Saharan Africa. Satish Gopal et al. Blood 2012;119:5078-5087 ©2012 by American Society of Hematology

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com Inc. All rights reserved.